(ICLR) ICON - Ratings and Ratios

ICON Public Limited Company (NASDAQ: ICLR) is a global clinical research organization specializing in outsourced development and commercialization services for the pharmaceutical, biotechnology, and medical device industries. Headquartered in Dublin, Ireland, and founded in 1989, ICON operates across Ireland, Europe, the United States, and internationally. The company provides comprehensive services spanning the entire clinical development process, from compound selection to Phase I-IV clinical studies, as well as peri and post-approval phases. Its offerings include clinical trial management, data solutions, site and patient access, consulting, and contract staffing. Additionally, ICON provides laboratory services such as bioanalytical, biomarker, vaccine, and good manufacturing practice (GMP) testing. The company also offers adaptive trials, decentralized and hybrid clinical trials, real-world intelligence, and medical imaging services. ICON serves a diverse range of clients, including government and public health organizations. Its expertise extends to strategic solutions, commercial positioning, and full-service partnerships. Visit their website at https://www.iconplc.com.

From a technical perspective, ICLR is currently trading at 136.79, below its 20-day SMA of 156.44 and 50-day SMA of 175.20, indicating short-term bearish momentum. The 200-day SMA of 240.21 suggests a longer-term downtrend. The ATR of 7.91 reflects moderate volatility. Based on these indicators, the stock may face resistance at the 50-day SMA level of 175.20 in the near term.

Fundamentally, ICONs market cap of $11.26 billion and P/E ratio of 14.62 indicate a relatively valued stock compared to industry peers. The forward P/E of 9.80 suggests potential undervaluation. The P/B ratio of 1.18 reflects assets being moderately valued relative to book value. The P/S ratio of 1.36 aligns with industry standards, and the RoE of 7.89% highlights modest profitability. These metrics collectively suggest stability and growth potential.

3-Month Forecast: Based on and , ICLR is expected to face short-term headwinds due to its current position below key moving averages. However, the companys strong fundamental position, including a reasonable P/S ratio and stable RoE, supports a recovery outlook. The stock is likely to test resistance at 175.20 in the next quarter, with potential upside if it breaks above this level.